Differential recognition of mdrla and mdrlb gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies
1992

Study of P-glycoprotein in Multidrug Resistant Mouse Tumor Cells

publication Evidence: moderate

Author Information

Author(s): M.A. Barrand, P.R. Twentyman

Primary Institution: MRC Clinical Oncology and Radiotherapeutics Unit

Hypothesis

The study aims to evaluate the reactivity of different monoclonal antibodies against P-glycoprotein in multidrug resistant mouse tumor cell lines.

Conclusion

Different monoclonal antibodies recognize distinct P-glycoprotein isoforms in mouse tumor cells, indicating variations in drug resistance mechanisms.

Supporting Evidence

  • C219 antibody stained resistant variants of both human and mouse tumor cell lines.
  • MRK 16 and JSB-1 recognized P-glycoprotein only in human MDR cell lines.
  • 265/F4 antibody was selective for the mdrlb P-glycoprotein in mouse cells.

Takeaway

Scientists looked at how different antibodies can see a protein that helps cancer cells resist drugs, and they found that some antibodies work better on certain types of cancer cells.

Methodology

The study used immunocytochemical methods, Western blotting, and PCR to analyze P-glycoprotein expression in various mouse and human tumor cell lines.

Limitations

The study primarily focuses on specific monoclonal antibodies and may not encompass all aspects of multidrug resistance.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication